Metronomic Cyclophosphamide and Methotrexate Combined With Zoledronic Acid and Sirolimus in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma. A Phase Ib Study From the French Sarcoma Group

Trial Profile

Metronomic Cyclophosphamide and Methotrexate Combined With Zoledronic Acid and Sirolimus in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma. A Phase Ib Study From the French Sarcoma Group

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Methotrexate (Primary) ; Sirolimus (Primary) ; Zoledronic acid (Primary)
  • Indications Osteosarcoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms METZOLIMOS
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.
    • 28 Sep 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
    • 03 Mar 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top